Castle Biosciences, Inc.
CSTL · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $344M | $332M | +3.7% |
| Operating income | −$42.8M | $8.67M | |
| Net income | −$24.2M | $18.2M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $103M | $83.0M | +24.0% |
| Operating income | −$2.70M | −$6.80M | +60.3% |
| Net income | −$4.10M | −$500K | −720% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Castle Biosciences's revenue in FY2025?
- $344M in FY2025 (Fiscal year ended Dec 31, 2025), +3.7% vs $332M a year earlier, per its 10-K filed Feb 2026.
- Was Castle Biosciences profitable in FY2025?
- No: net income was −$24.2M and operating income −$42.8M in FY2025.
- What was Castle Biosciences's revenue in Q3 2026?
- $103M (+24.0% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.